syn-010
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2015 (NCT02495623)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- HMG-CoA reductaseINHIBITOR
HMGCR inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- syn-010
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03763175 | Phase 2 | Dec 24, 2018 | Cedars-Sinai Medical Center, Synthetic Biologics |
| NCT02493036 | Phase 2 | Oct 1, 2015 | Synthetic Biologics |
| NCT02495623 | Phase 2 | Jun 1, 2015 | Synthetic Biologics |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Synthetic Biologics | For profit | 3 | 2 | 1 | 2015 |
| Cedars-Sinai Medical Center | Academic/Hospital | 1 | 1 | 1 | 2018 |
2 organizations
Page 1 / 1